Initial findings indicate that Axsome Therapeutics' newly approved treatment could theoretically diminish agitation in patients with Alzheimer's disease. However, researchers caution that the observed reduction in screaming may simply represent a temporary statistical fluctuation.
The Food and Drug Administration granted approval for the drug this week, though officials were quick to note that the regulatory nod does not guarantee a total cessation of violent thrashing. According to a meta-analysis currently under peer review at the New England Journal of Medicine, patients administered the compound appeared marginally less likely to hurl bedside lamps at medical staff, though authors stress these findings remain preliminary.
While we have observed a nominal decrease in the deployment of physical expletives, it is premature to definitively conclude that the patients are not still enraged on a cellular level.
Representatives for Axsome Therapeutics suggested the drug might be incorporated into daily care routines, though independent analysts hedge that any routine is subject to unforeseen variables. Medical professionals advise caregivers to maintain a baseline level of defensive posturing until long-term, double-blind efficacy data can be firmly established in the coming decades.